Clinical Trial Update: Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Recurrent Metastatic Melanoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating vaccine therapy with or without interleukin-2 in patients with recurrent metastatic melanoma; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Interleukin-2 (interleukin-2)
• vaccine therapy (unspecified)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Melanoma (Skin) | Phase 1 | Status: COMPLETED